BioCentury
ARTICLE | Company News

Enzon seeking alternatives for specialty pharma unit

August 12, 2008 1:20 AM UTC

Enzon (NASDAQ:ENZN) said it is exploring strategic alternatives for its specialty pharmaceutical business even as the company continues to pursue a plan to spin out its biotech business. The company said the alternatives it is considering include selling the entire specialty pharma business and selling its Indianapolis, Ind., manufacturing facility and one or more of the company's four marketed products, antifungal Abelcet, cancer drugs Oncaspar pegaspargase and DepoCyt Ara-C, and Adagen enzyme replacement therapy to treat severe combined immunodeficiency disease (SCID). Enzon said it has received "preliminary indications of interest" for the purchase of all or a portion of the business.

In May, Enzon said it would spin out a publicly traded company focused on developing cancer therapeutics using Enzon's PEGylation and Locked Nucleic Acid technologies (See BioCentury Extra, Wednesday, May 07, 2008). ...